← Back to Screener
Sarepta Therapeutics,, Inc. Common Stock (SRPT)
Price$21.42
Favorite Metrics
Price vs S&P 500 (26W)-11.28%
Price vs S&P 500 (4W)19.63%
Market Capitalization$2.24B
P/E Ratio (Annual)7.77x
All Metrics
Book Value / Share (Quarterly)$10.87
P/TBV (Annual)2.03x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)33.07%
Cash Flow / Share (Quarterly)$-3.00
Price vs S&P 500 (YTD)-4.00%
Gross Margin (TTM)69.33%
Net Profit Margin (TTM)-32.45%
EPS (TTM)$-7.24
10-Day Avg Trading Volume2.22M
EPS Excl Extra (TTM)$-7.24
Revenue Growth (5Y)32.41%
EPS (Annual)$-7.13
ROI (Annual)-36.22%
Gross Margin (Annual)69.33%
Net Profit Margin (5Y Avg)-39.65%
Cash / Share (Quarterly)$8.95
Revenue Growth QoQ (YoY)-32.73%
P/E Normalized (Annual)7.77x
ROA (Last FY)-21.30%
Revenue Growth TTM (YoY)15.58%
EBITD / Share (TTM)$-6.61
ROE (5Y Avg)-67.48%
Operating Margin (TTM)-31.07%
Cash Flow / Share (Annual)$-3.00
P/B Ratio1.97x
P/B Ratio (Quarterly)1.98x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)1.03x
Net Interest Coverage (TTM)-29.15x
ROA (TTM)-20.40%
EV / EBITDA (TTM)124.09x
EPS Incl Extra (Annual)$-7.13
Current Ratio (Annual)2.32x
Quick Ratio (Quarterly)1.44x
3-Month Avg Trading Volume2.89M
52-Week Price Return-60.05%
Revenue / Employee (TTM)$3
Tangible BV / Share (Quarterly)$10.59
P/S Ratio (Annual)1.02x
Asset Turnover (Annual)0.66x
52-Week High$64.80
Operating Margin (5Y Avg)-37.86%
EPS Excl Extra (Annual)$-7.13
CapEx CAGR (5Y)5.09%
Tangible BV CAGR (5Y)8.24%
26-Week Price Return-2.53%
Quick Ratio (Annual)1.44x
13-Week Price Return-5.48%
Total Debt / Equity (Annual)0.73x
Current Ratio (Quarterly)2.32x
Enterprise Value$2,270.798
Revenue / Share Growth (5Y)25.96%
Asset Turnover (TTM)0.63x
Book Value / Share Growth (5Y)2.52%
Revenue / Employee (Annual)$3
Inventory Turnover (Annual)0.81x
Pretax Margin (Annual)-31.94%
Cash / Share (Annual)$8.95
3-Month Return Std Dev94.58%
Gross Margin (5Y Avg)82.32%
Net Income / Employee (TTM)$-1
ROE (Last FY)-62.55%
Net Interest Coverage (Annual)-5.15x
EPS Basic Excl Extra (Annual)$-7.13
P/FCF (TTM)6.29x
Receivables Turnover (TTM)4.40x
Total Debt / Equity (Quarterly)0.73x
EPS Incl Extra (TTM)$-7.24
Receivables Turnover (Annual)4.40x
ROI (TTM)-31.35%
P/S Ratio (TTM)1.02x
Pretax Margin (5Y Avg)-38.74%
Revenue / Share (Annual)$21.96
Tangible BV / Share (Annual)$10.59
Forward P/E7.13x
Price vs S&P 500 (52W)-95.14%
Year-to-Date Return0.14%
5-Day Price Return-1.10%
EPS Normalized (Annual)$-7.13
ROA (5Y Avg)-13.51%
Net Profit Margin (Annual)-32.45%
Month-to-Date Return-0.97%
Cash Flow / Share (TTM)$-7.32
EBITD / Share (Annual)$-6.75
Operating Margin (Annual)-31.07%
LT Debt / Equity (Annual)0.73x
ROI (5Y Avg)-22.02%
LT Debt / Equity (Quarterly)0.73x
EPS Basic Excl Extra (TTM)$-7.24
P/TBV (Quarterly)2.03x
P/B Ratio (Annual)1.98x
Inventory Turnover (TTM)0.81x
Pretax Margin (TTM)-31.94%
Book Value / Share (Annual)$10.87
Price vs S&P 500 (13W)-8.35%
Beta0.28x
P/FCF (Annual)102.89x
Revenue / Share (TTM)$20.97
ROE (TTM)-57.52%
52-Week Low$10.42
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.36
3.36
3.36
3.42
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SRPTSarepta Therapeutics,, Inc. Common Stock | 1.02x | 15.58% | 69.33% | — | $21.42 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Sarepta Therapeutics is a commercial-stage biopharmaceutical company specializing in RNA-targeted and gene therapies for rare neuromuscular disorders. The company has four FDA-approved treatments for Duchenne muscular dystrophy and maintains a pipeline of additional candidates for neuromuscular and other rare diseases. Its integrated business model encompasses discovery through patient delivery of genetic medicines for underserved patient populations.